Strong Antiviral Activity of the New L-Hydroxycytidine Derivative, <scp>L</scp>-HYD4FC, In HBV-Infected Human Chimeric UPA/SCID Mice

Abstract

Administration of l-Hyd4FC in uPA/SCID mice harbouring HBV-infected human hepatocytes demonstrated the high antiviral potency of this drug in vivo. Such characteristics make l-Hyd4FC a good candidate for further investigations a as potential HBV therapeutic agent.